Passage Bio, Inc. (PASG)
After hours:
| Previous Close | 0.5360 |
| Open | 0.5400 |
| Bid | 0.5000 x 100 |
| Ask | 0.5133 x 100 |
| Day's Range | 0.5000 - 0.5613 |
| 52 Week Range | 0.4510 - 1.7900 |
| Volume | |
| Avg. Volume | 250,184 |
| Market Cap | 31.192M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1700 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.67 |
TipRanksPassage Bio Achieves Milestones in Gene Therapy Trials
Passage Bio ( (PASG) ) has issued an update. Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This
GlobeNewswirePassage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by stro
